Northwest Biotherapeutics traded at $0.23 this Thursday February 26th, decreasing $0.002 or 0.75 percent since the previous trading session. Looking back, over the last four weeks, Northwest Biotherapeutics lost 19.22 percent. Over the last 12 months, its price fell by 12.81 percent. Looking ahead, we forecast Northwest Biotherapeutics to be priced at 0.24 by the end of this quarter and at 0.22 in one year, according to Trading Economics global macro models projections and analysts expectations.
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to cover all solid tumor cancers in which the tumors can be surgically removed. It is on going Phase III trial for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company also offers a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.